GlassScriptPhysician profile
Thomas A Wroblewski
NPI 1891833612
$4,856.57
in general payments reported to CMS, 2019-2025
33 companies · $876 in 2025
The $876 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $310 · 2021: $963 · 2022: $895 · 2023: $829 · 2024: $663 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,368.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $749.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $744.99 | 2019-2024 | Arexvy, Bexsero, Shingrix |
| Amgen INC. | $685.08 | 2019-2025 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $422.46 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.71 | 2020-2024 | Xifaxan |
| Dexcom, INC. | $221.07 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $155.63 | 2022-2023 | |
| Renalytix Ai, INC. | $150.24 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Novartis Pharmaceuticals Corporation | $149.78 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $132.85 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $129.59 | 2022-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.14 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $103.34 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boston Scientific Corporation | $85.73 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $82.44 | 2019-2024 | Breztri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $68.79 | 2019-2025 | Veozah |
| Pfizer INC. | $61.55 | 2019-2024 | |
| Abbvie INC. | $40.67 | 2021-2023 | Synthroid |
| Janssen Biotech, INC. | $38.83 | 2025 | Tremfya |
| Amarin Pharma, INC. | $37.02 | 2020-2021 | |
| Almatica Pharma LLC | $35.01 | 2022 | |
| Exact Sciences Corporation | $31.84 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $28.47 | 2019-2021 | |
| Insulet Corporation | $25.38 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $21.91 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $19.89 | 2023 | Rexulti |
| Opko Pharmaceuticals, LLC | $19.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.54 | 2025 | Voquezna |
| Cmp Pharma, INC. | $19.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.21 | 2019 | |
| Esperion Therapeutics, INC. | $16.09 | 2021 | |
| Lundbeck LLC | $16.00 | 2024 | Vyepti |
| Abbott Laboratories | $15.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wroblewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.